reports
Xencor Reports First Quarter 2024 Financial Results
PASADENA, Calif.--(BUSINESS WIRE)-- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, today reported financial results for the first quarter ended March 31, 2024 and provided a review of recent clinical and business highlights. “We have focused our XmAb® clinical pipeline and discovery activities on bispecific CD3 and CD28 T cell engagers, which continue to show clinical validation for their potential in treating patients with serious diseases. Our key clinical-stage oncology program...
NVR Inc: 2 directors
Two Directors at NVR Inc sold/sold after exercising options 800 shares at between 7,665.630USD and 7,700.000USD. The significance rating of the trade was 75/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the comp...
- ABGSC Seafood Research
- Martin Kaland
- Simon Brun
Array Technologies, Inc. Reports Financial Results for the First Quart...
Array Technologies, Inc. Reports Financial Results for the First Quarter 2024 – Achieves record gross margin and $2.1 billion of executed contracts and awarded orders First Quarter 2024 Highlights Revenue of $153.4 millionGross Margin of 35.9%Adjusted gross margin of 38.3%(1)Net loss to common shareholders of $11.3 millionAdjusted EBITDA(1) of $26.2 millionBasic and diluted net loss per share of $0.07Adjusted diluted net income per share(1) of $0.06 ALBUQUERQUE, N.M., May 09, 2024 (GLOBE NEWSWIRE) -- Array Technologies (NASDAQ: ARRY) (“Array” or “the Company”), a leading...
Rigetti Computing Reports First Quarter 2024 Financial Results
Rigetti Computing Reports First Quarter 2024 Financial Results BERKELEY, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Rigetti Computing, Inc. (Nasdaq: RGTI) (“Rigetti” or the “Company”), a pioneer in full-stack quantum-classical computing, today announced its financial results for the first quarter ended March 31, 2024. First Quarter 2024 Financial Highlights Total revenues for the three months ended March 31, 2024 were $3.1 millionTotal operating expenses for the three months ended March 31, 2024 were $18.1 millionOperating loss for the three months ended March 31, 2024 was $16.6 milli...
Supernus Pharmaceuticals to Host Webcast to Review Interim Data from O...
Supernus Pharmaceuticals to Host Webcast to Review Interim Data from Ongoing Open-Label Phase IIa Study of SPN-817 for Treatment-Resistant Seizures ROCKVILLE, Md., May 09, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company will hold a webcast and conference call on Thursday, May 23, 2024, at 4:30 p.m. ET to review interim data from the open-label Phase IIa study of SPN-817 for treatment-resistant se...
INmune Bio Inc. Announces First Quarter 2024 Results and Provides Busi...
INmune Bio Inc. Announces First Quarter 2024 Results and Provides Business Update Company to Host Conference Call Today, May 9, at 4:30pm ET BOCA RATON, Fla., May 09, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, today announces its financial results for the quarter ended March 31, 2024 and provides a business update. Q1 2024 and Recent Corporate Highlights DN-TNF Platform Highlights (XPro™): The AD02 randomized, blinded program for patien...
Haynes International, Inc. Reports Second Quarter Fiscal 2024 Financia...
Haynes International, Inc. Reports Second Quarter Fiscal 2024 Financial Results Second quarter net revenues of $152.5 million with improving production momentum after last quarter’s three week unplanned outage at the 4-high hot rolling mill in the Kokomo plant. This compares to $147.4 million in the first quarter this year and $152.8 million in last year’s second quarter.Solid revenue growth in our core aerospace and industrial gas turbine markets this quarter compared to last year, largely offset by reductions in chemical processing and other marketsGross margin for the second quarter of 1...
Senti Bio Announces First Quarter 2024 Results and Reviews Recent Corp...
Senti Bio Announces First Quarter 2024 Results and Reviews Recent Corporate Highlights – First patient dosing of SENTI-202, a first-in-class logic-gated treatment for acute myeloid leukemia (“AML”), on track for the second quarter of 2024 – SOUTH SAN FRANCISCO, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio” or the “Company”), a biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today reported operational updates and financial results for the first quarter of 2024. ...
Phunware Reports Significant Improvement in First Quarter 2024 Financi...
Phunware Reports Significant Improvement in First Quarter 2024 Financial Results AUSTIN, Texas, May 09, 2024 (GLOBE NEWSWIRE) -- (“Phunware” or the “Company”), the leading provider of patented wayfinding and mobile engagement solutions that enables brands to engage, manage and monetize anyone anywhere, today announced financial results for the quarter ended March 31, 2024. “We’ve had a strong start to our year,” said Mike Snavely, CEO of Phunware. “New logo sales, gross margins and improvement in the strategic financial position of the company are the bright spots. We have the product, ...
Canterbury Park Holding Corporation Reports First Quarter Results
Canterbury Park Holding Corporation Reports First Quarter Results SHAKOPEE, Minn., May 09, 2024 (GLOBE NEWSWIRE) -- Canterbury Park Holding Corporation (“Canterbury” or the “Company”) (Nasdaq: CPHC), today reported financial results for the first quarter ended March 31, 2024. ($ in thousands, except per share data and percentages) Three Months Ended March 31, 2024 2023 ChangeNet revenues$14,098 $13,300 6.0% Net income $998 $2,771 -64.0% Adjusted EBITDA (1)$3,213 $2,818 14.0% Basic EPS$0.20 $0.57 -64.9%Diluted EPS$0.20 $0.56 -64.3% (1) Adjusted EBITDA, a non-GAAP...
Sensus Healthcare Reports First Quarter 2024 Financial Results With Re...
Sensus Healthcare Reports First Quarter 2024 Financial Results With Revenues up More than Three-fold Revenues of $10.7 million, compared with $3.4 million in the prior-year quarter; Adjusted EBITDA (a non-GAAP measure) of $3.0 million, compared with negative $2.7 million in the prior-year quarterLaunched the “Fair Deal Agreement” recurring revenue program to provide an equipment placement option and complement the fair market value lease program for SRT systems Conference call begins at 4:30 p.m. Eastern time today BOCA RATON, Fla., May 09, 2024 (GLOBE NEWSWIRE) -- Sensus Healthcare, In...
TELA Bio Reports First Quarter 2024 Financial Results
TELA Bio Reports First Quarter 2024 Financial Results MALVERN, Pa., May 09, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions today reported financial results for the first quarter ended March 31, 2024. Recent Highlights Reported revenue of $16.6 million in the first quarter, representing growth of 39% over the prior year period of 2023;Delivered the 13th consecutive quarter of at least 35% year-over-year growth;Increased demand for OviTex® and OviTex PRS Reinforced Tis...
Vor Bio Reports First Quarter 2024 Financial Results and Provides Comp...
Vor Bio Reports First Quarter 2024 Financial Results and Provides Company Update On-track for trem-cel and VCAR33ALLO clinical updates in the second half of 2024Trem-cel trial expanded to include patients with myelodysplastic syndromes (MDS); Mylotarg™ dosing has advanced to the third cohort CAMBRIDGE, Mass., May 09, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today reported financial results for the three-month period ended March 31, 2024, and provided a business update. “We are pleased with the strong enthusiasm from investig...
ARS Pharmaceuticals Highlights neffy Regulatory Progress and Reports F...
ARS Pharmaceuticals Highlights neffy Regulatory Progress and Reports First Quarter 2024 Financial Results neffy® (epinephrine nasal spray) New Drug Application (NDA) and CRL response under review by FDA with anticipated review completion by early October 2024 Response submitted for neffy Marketing Authorization Application (MAA) to EMA’s CHMP; CHMP opinion expected in the second quarter of 2024 Preparing to initiate outpatient study of neffy for urticaria (hives) in second half of 2024 $223.6 million in cash and securities as of March 31, 2024, providing an expected operating runway of a...
Morphic to Participate in RBC Capital Markets Global Healthcare Confer...
Morphic to Participate in RBC Capital Markets Global Healthcare Conference WALTHAM, Mass., May 09, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: MORF), a biotechnology company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced that Dr. Marc Schegerin, COO and CFO, will take part in a fireside chat at the 2024 RBC Capital Markets Global Healthcare Conference on Wednesday, May 15th, at 9:00 AM ET. A live webcast of the panel discussion and fireside chat at the RBC Global Healthcare Conference will be available on the Investor section ...
Adverum Biotechnologies Reports First Quarter 2024 Financial Results a...
Adverum Biotechnologies Reports First Quarter 2024 Financial Results and Provides Pipeline Highlights - Phase 2 LUNA interim analysis to be presented at ASRS Annual Scientific Meeting on July 17th, 2024 in Stockholm, Sweden - $193.3 million in cash, cash equivalents and short-term investments expected to fund operations into late 2025 REDWOOD CITY, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for highly prevalent ocular diseases, today reported financial resul...
Aqua Metals to Announce First Quarter 2024 Financial Results and Host ...
Aqua Metals to Announce First Quarter 2024 Financial Results and Host Investor Conference Call on May 15, 2024 RENO, Nev., May 09, 2024 (GLOBE NEWSWIRE) -- Aqua Metals, Inc. (NASDAQ: AQMS), a pioneer in sustainable lithium-ion battery recycling, today announced it will report financial results for the first quarter ended March 31, 2024, and provide a business update after the market closes on Wednesday, May 15, 2024. Following the release, management will host a conference call that same day at 4:30 p.m. ET. The live conference call can be accessed at or from the investor relations sect...
Profound Medical Announces First Quarter 2024 Financial Results and Is...
Profound Medical Announces First Quarter 2024 Financial Results and Issues Full-Year 2024 Revenue Guidance TORONTO, May 09, 2024 (GLOBE NEWSWIRE) -- (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today reported financial results for the first quarter ended March 31, 2024 and provided full-year 2024 revenue guidance. Unless specified otherwise, all amounts in this press release are expressed in U.S. dollars and are presented in accordance wi...
Notable Labs to Participate in Fireside Chat at the Citizens JMP Secur...
Notable Labs to Participate in Fireside Chat at the Citizens JMP Securities Life Sciences Conference 2024 FOSTER CITY, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Notable Labs, Ltd. (Nasdaq: NTBL) (“Notable”, “Notable Labs” or the “Company”), a clinical-stage precision oncology company developing new cancer therapies identified by its Predictive Medicine Platform (PMP), today announced that Thomas Bock, M.D., Chief Executive Officer of Notable Labs, will participate in a fireside chat at the Citizens JMP Securities Life Sciences Conference 2024, taking place on May 13-14, 2024, in New York C...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.